Difference in the Prognostic Significance of N-Terminal Pro-B-Type Natriuretic Peptide between Cardioembolic and Noncardioembolic Ischemic Strokes

Table 1

General characteristics of the study population; mean SD, (%).

	Cardioembolic source
	Present; = 221	Absent; = 189
Age, yr	67.7 ± 14.2	66.5 ± 13.6	0.401
Female gender	113 (51.1)	85 (45.0)	0.214
Hypertension	145 (65.6)	139 (73.5)	0.083
Diabetes	60 (27.1)	67 (35.4)	0.070
Hyperlipidemia	113 (51.1)	116 (61.4)	0.037
Current smoking	46 (20.8)	70 (37.0)	<0.001
Alcohol use	19 (8.6)	54 (28.6)	<0.001
Previous stroke	41 (18.6)	24 (12.7)	0.106
Ischemic heart disease	65 (29.4)	20 (10.6)	<0.001
Antiplatelet	107 (48.4)	59 (31.2)	<0.001
Warfarin	58 (26.2)	0 (0)	<0.001
Creatinine	1.14 ± 1.06	1.01 ± 1.09	0.221
NT-proBNP	3710.1 ± 7715.1	518.5 ± 2232.2	<0.001
NIHSS at admission	7.5 ± 8.8	4.7 ± 5.6	<0.001

NT-proBNP: N-terminal pro-B-type natriuretic peptide; NIHSS: National Institutes of Health Stroke Scale.